Skip to content
etf.net

BBC vs BBP

Virtus Biotech Clinical Trials ETF

BBCDNYSE Arca

Virtus Biotech ETF

BBPANYSE Arca

Overlap

Expense ratio

BBP −0.31pt a year

BBC0.65%BBP0.34%

Avg volume · 30D

BBC 2.1×the volume

BBC24.7KBBP11.7K

10Y return · a year

BBP +4.2pt

BBC+9.5%BBP+13.7%

BBC vs BBP Performance

Oct 29, 2021 – Oct 30, 2026

0.0%BBC+101.3%BBP

Oct 29, 2021 to Oct 30, 2026. BBC 0.0%. BBP +101.3%. Use the arrow keys to read each point.−50%−25%25%50%75%Oct 2021Apr 2024Oct 2026
Expense ratio
BBC 0.65%
BBP 0.34%, better
Fund size
BBC $35M
BBP $132M
1Y total return
BBC +35.6%
BBP +39.6%, better
Yield (12M)
BBC 1.52%, better
BBP 0.00%
Holdings
BBC 130
BBP 66
Avg volume (30D)
BBC 24.7K sh, better
BBP 11.7K sh
NAV per share
BBC $44.05
BBP $105.25
52W range

ETF.net Grade

BBC: Cost 13, Risk 12, Mission 45, Tradability 22, Holdings 93, Durability 48. BBP: Cost 94, Risk 64, Mission 83, Tradability 31, Holdings 82, Durability 55.
Pillar letters and Scores for BBC, BBP, with each pillar’s weight
PillarBBCBBP
Cost30% weightF13A94Higher
Mission25% weightC45A83Higher
Risk15% weightF12B64Higher
Tradability15% weightF22D31Higher
Holdings10% weightA93HigherA82
Durability5% weightC48B55Higher

Rank among Biotech & Genomics funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BBC and BBP are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds
See all 17 ›

BBP ranks 4th and BBC 16th of 17 funds in the Biotech & Genomics Category.

  1. Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
  2. Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
  3. Rank 3AIBBiShares Biotechnology ETFScore 75
  4. Rank 4ABBPVirtus Biotech ETFScore 74
  5. Rank 5BBBHVanEck Biotech ETFScore 68
  6. Rank 15DARKGARK Genomic Revolution ETFScore 33
  7. Rank 16DBBCVirtus Biotech Clinical Trials ETFScore 31
  8. Rank 17DCANCTema Oncology ETFScore 30

Our read on each fund

ETF.net Research

BBCDVirtus Biotech Clinical Trials ETF

BBPAVirtus Biotech ETF

In short

BBC Most biotech funds blend approved-drug cash machines with science projects. BBC keeps only the science projects: US-listed biotechs whose lead drug is still in clinical trials, spread across roughly 200 names.

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

Stated mandate

BBC The Fund seeks to track, before fees and expenses, the investment results of the LifeSci Biotechnology Clinical Trials Index. The Index comprises U.S.-listed biotechnology stocks with a lead drug in clinical-stage development.

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

Why people hold it

  • BBC A genuinely narrow mandate: the index takes U.S.-listed biotechs with a lead drug in clinical-stage development, so commercial-stage giants stay out.
  • Roughly 200 holdings, so one failed readout is a dent, not the whole fund.
  • The basket lines up tightly with what the prospectus says it owns, one of the cleaner mandate-to-portfolio matches in biotech.
  • Running since 2014, which makes it one of the longer-lived pure clinical-stage plays rather than a recent theme launch.
  • BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
  • 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
  • Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
  • One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

Worth knowing

  • BBC At 0.65% a year it costs more than the typical biotech fund, and more than broad peers like XBI (0.35%) and IBB (0.44%).
  • Small asset base and thin trading, so spreads can widen and large orders move the price.
  • Pre-approval biotech is binary by nature, and on our review the fund sits in the lower tier of its biotech peer group overall.
  • BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
  • Income is not the point here. The fund has not been paying distributions, so the return story is price.
  • An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

Full BBC profile⁠

Full BBP profile⁠

BBC vs BBP Holdings

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BBC vs BBP Cost

Overpaying BBC vs BBP

$5,785

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BBC 0.65%

    $12,717

  • BBP 0.34%

    $6,932

$10,000
30 years

Cost over time

  • BBC 0.65%
  • BBP 0.34%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K051015202530BBC $12,717BBP $6,932

Year by year

YearBBCBBPOverpaying
10$1,163$616$547
20$4,440$2,386$2,054
30$12,717$6,932$5,785

Expense ratio

  • 0.65%BBC
  • 0.34%BBP, cheaper
  • Middle half of Biotech & Genomics funds
  • Median 0.47%

BBP 2nd cheapest of 17 funds

BBC 15th cheapest of 17 funds

BBC vs BBP Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
BBC 1.52%, better
BBP 0.00%
Payout (12M)
BBC $0.66
BBP None
Last payment
BBC $0.66
BBP No data
Ex-dividend
BBC Dec 22, 2025
BBP No data
Paid on
BBC Dec 29, 2025
BBP No data
Frequency
BBC Annual
BBP No data

Distribution history

Per share, 2017 to 2026, same scale for both

BBCAnnual · 4 paymentsAll BBC payments⁠
One bar per payment. 4 payments from 2017 to 2026 YTD. Dec 20, 2017 $0.30; Dec 20, 2023 $0.08; Dec 20, 2024 $0.24; Dec 22, 2025 $0.66. Use the arrow keys to read each point.$0$0.502017202020232026YTD
BBP1 paymentAll BBP payments⁠
One bar per payment. 1 payment from 2017 to 2026 YTD. Dec 20, 2017 $0.07. Use the arrow keys to read each point.$0$0.502017202020232026YTD

BBC vs BBP Risk

Fall from peak · 5 years

  • BBC
  • BBP
Oct 29, 2021 to Oct 30, 2026. Worst fall: BBC −70.1% · Apr 2025. Use the arrow keys to read each point.−60%−40%−20%0%Oct 2021Apr 2024Oct 2026

Risk facts

VolatilityStd dev, 3 years
BBC 35.7%BBP 18.7%, better
Return per unit of riskSharpe ratio, 3 years
BBC 0.90BBP 1.30, better
Worst fallMax drawdown, 5 years
BBC −70.1%BBP −37.8%, better
Market sensitivityBeta, 5 years
BBC 1.31BBP 0.77

BBC and BBP in the news

All news⁠

Popular comparisons

  • BBCDvsXBIA

    Virtus Biotech Clinical Trials ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.65% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsXBIA

    Virtus Biotech ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.34% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBCDvsIBBQA

    Virtus Biotech Clinical Trials ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.65% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBQA

    Virtus Biotech ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.34% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBCDvsIBBA

    Virtus Biotech Clinical Trials ETF · iShares Biotechnology ETF

    Expense ratio
    0.65% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBA

    Virtus Biotech ETF · iShares Biotechnology ETF

    Expense ratio
    0.34% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.